Occupational exposure to cytotoxic drugs: the importance of surface cleaning to prevent or minimise exposure
暂无分享,去创建一个
[1] S. Viegas,et al. Genotoxicity assessment of a selected cytostatic drug mixture in human lymphocytes: A study based on concentrations relevant for occupational exposure , 2018, Environmental research.
[2] S. Viegas,et al. Forgotten public health impacts of cancer – an overview , 2017, Arhiv za higijenu rada i toksikologiju.
[3] G. Gajski,et al. Combined cyto/genotoxic activity of a selected antineoplastic drug mixture in human circulating blood cells. , 2016, Chemosphere.
[4] P. Bonnabry,et al. Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study , 2016, PloS one.
[5] E. Davoli,et al. Antineoplastic drugs determination by HPLC-HRMS(n) to monitor occupational exposure. , 2016, Drug testing and analysis.
[6] S. Viegas,et al. How to deal with uncertainties regarding the occupational exposure to antineoplastic mixtures: additive effect should always be considered? , 2016 .
[7] W. Feng,et al. Evaluation of adverse health risks associated with antineoplastic drug exposure in nurses at two Chinese hospitals: The effects of implementing a pharmacy intravenous admixture service. , 2016, American journal of industrial medicine.
[8] A. Turner,et al. Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[9] J. Bussières,et al. Surface Contamination in a Teaching Hospital: A 6 Year Perspective , 2016 .
[10] S. Rudaz,et al. Evaluation of chemical contamination of surfaces during the preparation of chemotherapies in 24 hospital pharmacies , 2015 .
[11] E. Ceretti,et al. Micronuclei and chromosome aberrations in subjects occupationally exposed to antineoplastic drugs: a multicentric approach , 2015, International Archives of Occupational and Environmental Health.
[12] M. McDiarmid,et al. Reproductive Health Risks Associated With Occupational Exposures to Antineoplastic Drugs in Health Care Settings: A Review of the Evidence , 2014, Journal of occupational and environmental medicine.
[13] S. Viegas,et al. Antineoplastic drugs contamination of workplace surfaces in two Portuguese hospitals , 2014, Environmental Monitoring and Assessment.
[14] M. Sweeney,et al. Adherence to Safe Handling Guidelines by Health Care Workers Who Administer Antineoplastic Drugs , 2014, Journal of occupational and environmental hygiene.
[15] K. Kümmerer,et al. Environmental risk assessment of anti-cancer drugs and their transformation products: A focus on their genotoxicity characterization-state of knowledge and short comings. , 2014, Mutation research. Reviews in mutation research.
[16] T. de Jong,et al. Current and emerging occupational safety and health (OSH) issues in the healthcare sector, including home and community care , 2014 .
[17] J. Tuerk,et al. Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies - the MEWIP project. , 2013, The Annals of occupational hygiene.
[18] P. Bonnabry,et al. Evaluation of decontamination efficacy of cleaning solutions on stainless steel and glass surfaces contaminated by 10 antineoplastic agents. , 2013, The Annals of occupational hygiene.
[19] P. Hartemann,et al. Environmental impact of medical prescriptions: assessing the risks and hazards of persistence, bioaccumulation and toxicity of pharmaceuticals. , 2013, Public health.
[20] Jason S. Trahan,et al. Reduction in Surface Contamination with Cyclophosphamide in 30 US Hospital Pharmacies following Implementation of a Closed-System Drug Transfer Device , 2013, Hospital pharmacy.
[21] Jing-Yuan Wang,et al. Removal of cytostatic drugs from aquatic environment: a review. , 2013, The Science of the total environment.
[22] M. Imbriani,et al. Occupational exposure to antineoplastic drugs in four Italian health care settings. , 2012, Toxicology letters.
[23] J. Garric,et al. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs? , 2012, Environment international.
[24] S. Singh,et al. Monitoring of Oxidative Stress in Nurses Occupationally Exposed to Antineoplastic Drugs , 2012, Toxicology international.
[25] D. Nowak,et al. Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings , 2012, International Archives of Occupational and Environmental Health.
[26] M. Imbriani,et al. Occupational exposure to antineoplastic drugs in seven Italian hospitals: The effect of quality assurance and adherence to guidelines , 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[27] V. Castagné,et al. Cytotoxics compounded sterile preparation control by HPLC during a 16-month assessment in a French university hospital: importance of the mixing bags step , 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[28] K. Teschke,et al. Occupational Exposure to Antineoplastic Drugs: Identification of Job Categories Potentially Exposed throughout the Hospital Medication System , 2011, Safety and health at work.
[29] E. Heath,et al. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment , 2011 .
[30] S. Kumagai,et al. Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan , 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[31] P. Sessink,et al. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device , 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[32] B. Rogers,et al. Chromosome 5 and 7 Abnormalities in Oncology Personnel Handling Anticancer Drugs , 2010, Journal of occupational and environmental medicine.
[33] Ludek Blaha,et al. Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. , 2010, Chemosphere.
[34] É. Langlois,et al. Pilot study comparing the efficacy of two cleaning techniques in reducing environmental contamination with cyclophosphamide. , 2010, The Annals of occupational hygiene.
[35] D. Nowak,et al. Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. , 2009, The Annals of occupational hygiene.
[36] É. Langlois,et al. Evaluation of surface contamination in a hospital hematology—oncology pharmacy , 2009, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[37] J. Saffi,et al. Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week. , 2008, Mutagenesis.
[38] G. Poggi,et al. Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation. , 2008, Rapid communications in mass spectrometry : RCM.
[39] N. Miraglia,et al. Evaluation of Occupational Exposure to Antiblastic Drugs in an Italian Hospital Oncological Department , 2008, Journal of occupational health.
[40] H. Kromhout,et al. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. , 2007, The Annals of occupational hygiene.
[41] S. Iavicoli,et al. Micronucleus induction and FISH analysis in buccal cells and lymphocytes of nurses administering antineoplastic drugs. , 2007, Mutation research.
[42] H. Kromhout,et al. Nurses With Dermal Exposure to Antineoplastic Drugs: Reproductive Outcomes , 2007, Epidemiology.
[43] V. Garaj-Vrhovac,et al. Alkaline comet assay study with breast cancer patients: evaluation of baseline and chemotherapy-induced DNA damage in non-target cells , 2006, Clinical and Experimental Medicine.
[44] H. Kromhout,et al. Exposure to antineoplastic drugs outside the hospital environment. , 2006, The Annals of occupational hygiene.
[45] T. Connor. Hazardous Anticancer Drugs in Health Care , 2006, Annals of the New York Academy of Sciences.
[46] Q. M. Khan,et al. Cytogenetic analysis of Pakistani individuals occupationally exposed to pesticides in a pesticide production industry. , 2006, Mutagenesis.
[47] Sergio Iavicoli,et al. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. , 2005, Mutation research.
[48] S. Eksborg,et al. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. , 2005, The Annals of occupational hygiene.
[49] F. Violante,et al. A new high-performance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring. , 2005, Journal of mass spectrometry : JMS.
[50] C. Minoia,et al. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[51] R. Schierl,et al. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[52] R. Larson,et al. Monitoring method for surface contamination caused by selected antineoplastic agents. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[53] D. Loffredo,et al. Low-Level (PPB)Determination of Cisplatin in Cleaning Validation (Rinse Water) Samples. II. A High-Performance Liquid Chromatogrphic Method , 2000, Drug development and industrial pharmacy.
[54] P. Sessink,et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[55] P. Sessink,et al. Drugs Hazardous to Healthcare Workers , 1999, Drug safety.
[56] P. Apostoli,et al. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. , 1998, Rapid communications in mass spectrometry : RCM.
[57] A. Fucic,et al. Cytogenetic consequences after occupational exposure to antineoplastic drugs. , 1998, Mutation research.
[58] J. Cvačka,et al. Chemical degradation of wastes of antineoplastic agents amsacrine, azathioprine, asparaginase and thiotepa. , 1998, The Annals of occupational hygiene.
[59] J T Walker,et al. Validation of cleaning procedures for highly potent drugs. II. Bisnafide. , 1998, Pharmaceutical development and technology.
[60] G. Duménil,et al. Chemical degradation of wastes of antineoplastic agents: cyclophosphamide, ifosfamide and melphalan , 1996, International archives of occupational and environmental health.
[61] M. Castegnaro,et al. Chemical degradation of wastes of antineoplastic agents , 1997 .
[62] M. Castegnaro,et al. Chemical degradation of wastes of antineoplastic agents. 2: Six anthracyclines: idarubicin, doxorubicin, epirubicin, pirarubicin, aclarubicin, and daunorubicin. , 1997, International archives of occupational and environmental health.
[63] J T Rubino,et al. Validation of cleaning procedures for highly potent drugs. I. Losoxantrone. , 1996, Pharmaceutical development and technology.
[64] P. Sessink,et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. , 1994, Mutation research.
[65] M. Caira,et al. X-ray structural characterization of anhydrous metronidazole benzoate and metronidazole benzoate monohydrate. , 1993, Journal of pharmaceutical sciences.
[66] J. Benvenuto,et al. Degradation and inactivation of antitumor drugs. , 1993, Journal of pharmaceutical sciences.
[67] Eric B. Sansone,et al. Degradation and disposal of some antineoplastic drugs. , 1989, Journal of pharmaceutical sciences.
[68] J. Benvenuto,et al. Stability and inactivation of mutagenic drugs and their metabolites in the urine of patients administered antineoplastic therapy , 1987, Environmental and molecular mutagenesis.
[69] D. Gompertz,et al. MUTAGENICITY OF URINE FROM NURSES HANDLING CYTOTOXIC DRUGS , 1984, The Lancet.
[70] Pham-Huu-Chanh,et al. Some biological effects of thyronamine. , 1966, Medicina et pharmacologia experimentalis. International journal of experimental medicine.